san jose collage
San Jose
Serving San Jose, California (Santa Clara County)Vol. 1, No. 23
Government

Walk in ready to quit opioids, leave with a long-acting treatment shot:  San Francisco starts same-day injections at a major homeless clinic

A $500,000 pilot pays for 460 first doses at the Maria X Martinez Health Resource Center, where most of the 21,000 yearly patients are homeless.

ShareFacebookXEmail
Gloved hands in a blue medical sleeve hold a syringe next to a small unlabeled vial on a white tray in a bright clinic exam room, with a blue exam chair, a large window and an open doorway behind them.
An AI-generated illustration of a clinic exam room where a long-acting injection is prepared. — Illustration: AI-generated for Daily News

People ready to treat an opioid addiction can now get their first shot of a long-acting medicine the same day at one of San Francisco’s largest clinics for homeless residents, the city’s Department of Public Health said Friday.

What the pilot changes

The pilot at the Maria X Martinez Health Resource Center lets the clinic store and give long-acting injectable buprenorphine on site for the first time, without the extra steps that used to delay care.  The center sees more than 21,000 patients a year, and more than 75% of them are homeless, the department said.

Clinicians said many patients, especially those using fentanyl, find withdrawal so hard that coming back another day is not realistic.  The department’s Street Team can now bring people straight from outreach to the clinic for treatment in one visit.  The shot also helps people who struggle to take a daily dose, it said.

How long the shots last

The department did not say which brand the clinic uses. The U.S. Food and Drug Administration has approved two long-acting buprenorphine shots: Sublocade, given once a month, and Brixadi, given once a week or once a month. Buprenorphine eases cravings and withdrawal by partly acting on the same brain receptors as opioids. The shot goes under the skin, where it forms a small deposit that slowly releases the medicine, so patients don’t need a daily pill or film.

Under Sublocade’s federal label, a new patient first takes one small dose of buprenorphine under the tongue, then gets the shot and is watched at the clinic until symptoms are stable or improving. The second shot can come as soon as a week later. After two starting doses of 300 milligrams, patients usually get a 100-milligram shot every month.

What the shots cost

Sublocade’s list price is $2,202.03 per monthly shot for either strength, according to its maker, the drug company Indivior. Most patients pay much less: the company says almost 90% of people on Medicaid, the government health plan for low-income people, pay nothing. In San Francisco’s pilot, the grant buys the doses.

How well they work

In the main 24-week study behind Sublocade’s approval, published in The Lancet in 2019, patients getting the monthly shot were free of illegal opioids about 41% to 43% of the time, based on urine tests and their own reports, compared with 5% for patients given a fake shot. In a later study of 729 people, most of whom had fentanyl in their urine, 66.4% of those started on the shot in a single visit came back for a second one, compared with 54.5% of those who first took daily doses under the tongue for at least a week, Indivior said.

How many shots treatment takes

There is no set number of shots that completes treatment. The federal Substance Abuse and Mental Health Services Administration (SAMHSA) says the length of buprenorphine treatment is tailored to each patient and can be indefinite. Its prescribing guide says a fixed treatment length is not recommended, and patients who want to stop are usually tapered off slowly over several months because of the risk of relapse and overdose.

Who pays, and what comes next

The pilot costs about $500,000 from the Breaking the Cycle Fund, a public-private fund that is part of Mayor Daniel Lurie’s homelessness and behavioral health effort.  Most of the money buys 460 first doses and 500 follow-up doses over two years.  It runs through April 2028 and may expand to up to five more city clinics in 2027.

The department said it will track overdoses, emergency room visits, hospital stays and how many people stay in treatment.  The shot was already available on demand at Zuckerberg San Francisco General Hospital, the city’s Sobering Center, its Behavioral Health Services Pharmacy and the BEAM program at 1380 Howard St.

Sources: San Francisco Department of Public Health, Nov. 13, 2026; FDA Sublocade label, February 2025; FDA, May 23, 2023; Indivior price disclosure and savings page; Haight et al., The Lancet, Feb. 18, 2019; Indivior, Feb. 24, 2025; SAMHSA; SAMHSA prescribing guide, 2021.

Drafted by AI from the linked public source. Approved by a Daily News Editor.

Sources and documents